Trial Profile
Safety of conversion from Sirolimus to Everolimus-based immunosuppression in long-term liver graft recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Liver transplant rejection
- Focus Adverse reactions
- 07 Feb 2017 New trial record
- 30 Jan 2017 Results published in the Journal of Clinical Pharmacology